AcZon srl

ProteoGenix is a leading life sciences organization which provides services in molecular biology and immunology and in particular polyclonal and monoclonal antibody development, recombinant protein expression and purification, peptide synthesis as well as gene synthesis. ProteoGenix’s commitment to its clients is to ensure the access to comprehensive and integrated solutions to help our customers develop the tools they need to efficiently conduct their biology and research projects in a time effective manner.

Beginning with the synthesis of the gene ProteoGenix develops all the materials required for immunoassay services. Proteogenix’s exceptional and functional expertise combined with our extensive scientific knowledge and experience ensures ProteoGenix to be a reliable partner for your antibodies, proteins, genes (cDNA) and peptides.
Our custom services ensure a unique and tailored process to our clients revolving around four areas :

Protein expression and purification in E. Coli, Yeast, Insect cells (baculovirus) and Mammalian Cells
Monoclonal antibody production and Polyclonal antibody production
Gene synthesis, sub-cloning and mutagenesis
Peptide synthesis, purification and conjugation

ProteoGenix also provides the research and academic communities with a wide range of commercial products available on our website such as antibodies, proteins, ELISA kits, tissue microarrays, chimera RNAi, molecular biology products as well as many more.

Pioneer in antibodies’ field, Agro-Bio provides you its expertise and its know-how for production, development and characterization of antibodies. For over 40 years, our team supports pharmaceutical and in vitro diagnostic industries as well as public institutions for their immunology issues. We collaborate both to offer you the most suitable and effective solution. Our goal is the success of your projects.

Our services around antibody:
• Bioanalysis/Biopharma:
o Anti-idiotypic antibodies for positive control, PK and potency test,
o Host Cell Protein issue management: specific anti-HCP antibodies, 2D Western Blot coverage analysis, specific ELISA kit,
o Epitope mapping,
o In vitro production.
• In vitro diagnostic:
o Bulk antibody production,
o Specific polyclonal and monoclonal antibody development,
o Characterization of antibodies: Biacore T200…

Our key strengths to ensure a quality work:
• Over 40 years’ experience in antibody area,
• Responsive, multi-skilled and comprehensive team,
• Certifications ISO 90001:2015 and ISO 13485:2016,
• Research Taxe Credit approval,
• Preserved intellectual propriety and confidentiality,
• Transparency for monitoring and management of your project,
• Royalty-free services.

💡 A biotechnology group based on complementary expertise with multidisciplinary know-how

Custom Products & Services delivering a range of integrated biotechnology solutions 🤝

🏢 COMPANIES:

- RD-Biotech SAS (www.rd-biotech.com):
Custom services, Biomanufacturing and purification (monoclonal antibodies, recombinant proteins, plasmids, cells), hybridoma development, expression vectors, transfection, antibody sequencing, chimerization and humanization, analytical services and FastELISA kits for Immunoglobulins quantification and cellular contaminants detection.

- SYnAbs (www.synabs.be):
Primary and Secondary Antibodies Anti-species, Isotype controls, custom services, hybridoma development – rat, guinea pig, murine, Immunoassays

- QVQ (www.qvquality.com)
VHH Phage display services and a large range of VHH products

- Smaltis (www.smaltis.fr)
CRO specialized in microbiology, an high expertise in the fileds of antibiotic resistance, microbiota and strain engineering. Custom services and a large collection of genetically modified bacterial strains.

📈 EFFECTIVE SYNERGY

As part of a team of experts to ensure:
- The development of new biological tools in immunology, molecular biology, cellular engineering
- Identification of new markers
- The development of analytical methods
- Scientific and technical support
- The quality of services and products developed and manufactured in-house

✔ MAIN SECTORS OF ACTIVITY

- Pharmaceutical
- BioTherapeutics
- Biotechnology
- In vitro diagnostics
- Animal health
- Dermo-cosmetic
- Agribusiness
- Life sciences
- Environment
- Research Institutes

EXBIO is the leading manufacturer of monoclonal antibodies and reagents for research and clinical applications with the focus on multi-color flow cytometry analysis of human cellular markers.
Our comperhensive portfolio of more than 4 000 off-the-shelf products covers a diverse set of areas including Hematology, Immunology, Cancer, Stem cells, and Cell Biology. With the experienced cytometry experts and biotech engineers, EXBIO offers to our customers long-term validated antibody markers in the broad selection of fluorochrome conjugates.

Our commitment to the customer's needs, supported by our integrated quality management system compliant with ISO 13485:2016, ISO9001:2015 and cGMP (21 CFR part 820), allow us to accomplish our mission:

EXBIO strives to exceed the most demanding customer expectations in the field of analytical cytometry by providing a comprehensive portfolio of high quality products and services at affordable prices.

Who we are?

Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of antibody-based COVID-19 compounds.

What are Biosimilars?
Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of more than USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. While the global market for biosimilars is currently more than USD 5.0 billion, industry experts expect this figure to grow up to USD 30 billion by the year 2025.

Contact:
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg
Germany
phone +49 (0) 89 - 86 46 67 100
fax + 49 (0) 89 - 86 46 67 110
info@formycon.com // www.formycon.com